Quick Search

This question has been contemplated for years and still there is controversy over the issue. Most recently a study that was reported in the press indicated that there was no advantage to have a mammogram until age 50. While a large study like this holds some weight, it still leaves many questions unanswered.

The U.S. Court of Appeals recently ruled that "a terminally ill patient with no government-approved treatment option has a constitutional right to access investigational drugs that have completed Phase I trials."

Smoke-Free Mecklenburg is a local grassroots coalition of health care professionals, advocacy groups and individuals committed to bringing smoke-free restaurants, bars and workplaces to Mecklenburg County

Roche Laboratories announced that the oral form of 5-fluoruracil, Xeloda, is just as effective in long-term studies as the more common intravenous form when given in combination with oxaliplatin.

The STAR (Study of Tamoxifen and Raloxifene) trial, an initiative of the National Surgical Adjuvant Breast and Bowel Project (NSABP) that compared the use of tamoxifen (Nolvadex) and raloxifene (Evista) in the prevention of breast cancer in high-risk women, recently yielded some early data.

A recent study was just published in the Journal of the American Medical Association (JAMA) on the outcomes of patients with known prostate cancer but very early stage that were treated conservatively, that is, without surgery, chemotherapy or radiation therapy.

Two large studies, in which Presbyterian Cancer Center was a participant, have analyzed early data and on the basis of significant better outcomes will stop accrual, or putting new patients on the trial.

Cancer has passed heart disease as the number one killer of Americans under age 85.

Learn how gene profiles may affect treatment for breast cancer.

Learn why Arimidex is now the treatment of choice.

How Mrs. Edwards' care is similar to the care we provide at Presbyterian.

What the Vioxx controversy means to cancer patients.

Learn more about this change.